Challenges of general safety evaluations of biologics compared to small molecule pharmaceuticals in animal models

Expert Opinion on Drug Discovery

Volumn 5, Issue 1, 2010, Pages 79-94

  Dixit, Rakesh ^a   Iciek, Laurie A ^a   McKeever, Kathleen ^a   Ryan, Patricia Clare ^a  

^a MEDIMMUNE   (United States)

Author keywords

Animal models; Antibodydrug conjugates; Biologics; Drugdevelopment; Immunotoxins; MAbs; Oligonucleotides; Recombinant proteins; Safety evaluation; Small molecules; Toxicology; Vaccines

Indexed keywords

IMMUNOTOXIN; MONOCLONAL ANTIBODY; OLIGONUCLEOTIDE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RITUXIMAB;

DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG SCREENING; HUMAN; IMMUNIZATION; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RISK ASSESSMENT; VIRUS INFECTION;

EID: 73649107318     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440903443410     Document Type: Review

References (68)

1. Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000;32:56-67
2. Rituximab BLA. Available from: http:// www.accessdata.fda.gov/scripts/ cder/ drugsatfda/index.cfm
3. ICH S6, Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals, July 1997Available from: http://www.ich.org
4. US Food and Drug Administration Center for Biologics Evaluation and Research, "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use", Feb 28, 1997
5. Bussiere JL, Martin P, Horner M, et al. Alternative strategies for toxicity testing of species-specific biopharmaceuticals. Int J Toxicol 2009;28(3):230-253
6. Ferrara C, Stuart F, Sondermann P, et al. The Carbohydrate at FcgammaRIIIa Asn-162: an element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006;281(8):5032-5036
7. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006;281:23514-23524
8. Krolick KA, Villemez C, Isakson P, et al. Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc Natl Acad Sci USA 1980;77:5419-5423
9. Pastan I, FitzGerald D. Pseudomonas exotoxin: chimeric toxins. J Biol Chem 1989;264:15157-15160
10. Pastan I. Immunotoxins containing pseudomonas exotoxin A: a short history. Cancer Immunol Immunother 2003;52:338-341
11. Herschman HR, Simpson DL, Cawley DB. Toxic ligand conjugates as tools in the study of receptor-ligand interactions. J Cell Biochem 1982;20:163-176
12. Brown JG, Entwistle J, Glover N, Macdonald GC. Preclinical safety evaluation of immunotoxins. In: J Cavagnaro, editor, Preclinical safety evaluation of biopharmaceuticals: a science-based approach to facilitating clinical trials, John Wiley & Sons, Hoboken, NJ; 2008. p. 649-667
13. Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 2009;23(1):1-13
14. Hwang J, FitzGerald DJ, Adhya S, Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. Coli. Cell 1987;48:129-136
15. Kondo K, FitzGerald DJ, Chaudhary V. Activity of immunotoxins constructed with modified Pseudomonas exotoxin a lacking the cell recognition domain. J Biol Chem 1988;263(19):9470-9475
16. Jinno Y, Chaudhary VK, Kondo T, et al. Mutational analysis of domain I of Pseudomonas Exotoxin. Mutations in domain I of Pseudomonas exotoxin which reduce cell binding and animal toxicity. J Biol Chem 1988;263(26):13203-13207
17. Siegall CB, Chaudhary V, FitzGerald DJ, Pastan I. Functional analysis of domains II, Ib and III of pseudomonas exotoxin. J Biol Chem 1989;264:14256-14261
18. Onda M, Nagata S, FitzGerald DJ, et al. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas Exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 2006;177:8822-8834
19. Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clin Cancer Res 2000;6:334
20. Siegall CB, Liggitt D. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc Natl Acad Sci USA 1994;91:9514-9518
21. ICH M3 (R1), Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, November 2000Available from: http:// www.ich.org. ICH M3 (R2), Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, July 2008. Available from: http://www.ich.org
22. Grimm D, Kay MA. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 2007;117(12):3633-3641
23. Aigner A. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol 2007;76:9-21
24. Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs. Cell 2006;126:231-235
25. Burley SK, Park F. Meeting the challenges of drug discovery: a multidisciplinary re-evaluation of current practices. Genome Biol 2005;6:330.1-330.3
26. Barik S, Bitko V. Prospects of RNA interference therapy in respiratory viral diseases: update 2006. Expert Opin Biol Ther 2006;6(11):1151-1160
27. Bitko V, Musiyenko A, Shulyayeva O, et al. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005;11(1):50-55
28. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotech 2005;23(8):1002-1007
29. Zender L, Kubicka S. SiRNA based strategies for inhibition of apoptotic pathways in vivo-analytical and therapeutic implications. Apoptosis 2004;9:51-54
30. Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitization of malignant melanoma by BCL2 antisense therapy. Lancet 2000;356:1728-1733
31. AthyrosVG,KakafikaAI,TziomalosK, et al. Antisense technologyfor thepreventionorthe treatment of cardiovascular disease: the next blockbuster? Expert Opin Invest Drugs 2008:17(7):969-972
32. Levin AA, Henry SP. Toxicology of oligonucleotide therapeutics and understanding the relevance of the toxicities. In: J Cavagnaro, editor, Preclinical safety evalution of biopharmaceuticals: a science-based approach to facilitating clinical trials, JohnWiley&Sons,Hoboken, NJ; 2008. p. 537-574
33. Black LE, Farrelly JG, Cavagnaro JA, et al. Regulatory considerations of oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies. Antisense Res Dev 1994;4:299-301
34. Black LE, DeGeorge JJ, Cavagnaro JA, et al. Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs. Antisense Res Dev 1993;3:399-404
35. Jackson AL, Burchard J, Schelter J, et al. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 2006;12:1179-1187
36. Verdel A, Jia S, Gerber S, et al. RNAI-mediated targeting of heterchrome by the RITS complex. Science 2004;303(5658):672-676
37. HenrySP,NovotnyW,LeedsJ,etal.Inhibition of coagulation by a phosphorothioate oligonucleotide. AntisenseNucl Acid Drug Dev 1997;7:503-510
38. Sheehan JP, Lan H-C. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 1998;92(5):1617-1625
39. Sheehan JP, Thao PM. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry 2001;40(16):4980-4989
40. Henry SP, Giclas PC, Leeds J, et al. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 1997;281(2):810-816
41. Henry SP, Beattie G, Yeh G, et al. Complement activation is responsible for acute toxicities inrhesusmonkeys treatedwith a phosphorothioate oligodeoxynucleotide. Int J Immunopharmacol 2002;2(12):1657-1666
42. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004;4(4):249-258
43. FDA G95-1 guidance. Available from: http://www.fda.gov/cdrh/g951.html
44. US FDA CBER Guidance for Human Somatic Cell Therapy and Gene Therapy. Available from: http://www.fda.gov/ downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatory Information/Guidances/ CellularandGeneTherapy/ ucm081670.pdf
45. ICH S9, Nonclinical Evaluation for Anticancer Pharmaceuticals, Step 3, December 2008,US Food and Drug Administration Center for Biologics Evaluation and Research, Guidance for Industry, Considerations for plasmid DNA Vaccines for Infectious Disease Indications, November 2007Available from: http://www.ich.org
46. USA FDA Nonclinical Safety Evaluation of Pediatric Drug Products guidance. Available from: http://www.fda.gov/ downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/ucm079247.pdf
47. EMEA. CHNP SWP Reflection Paper on the Assessment of the Genotoxic Potential of Antisense Oligodeoxynucleotides. EMEA/CHNP/SWP199726/2004 (2005). Available from: www.emea. europa.eu/pdfs/human/swp/ 19972604en.pdf
48. Sutkowski EM, Gruber MF. Non-clinical Safety evaluation of preventive vaccines-regulatory considerations, business briefing. Future Drug Discov 3rd edition, June 2003;34-37
49. Ball R. Methods of ensuring vaccine safety. Expert Rev Vaccines 2002;1(2):161-168
50. World Health Organization Guidelines on Nonclinical Evaluation of Vaccines, WHO Expert Committee on Biological Standardization, November, 2003
51. European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products, Points to Consider on the Development of Live attenuated Influenza Vaccines, February 20, 2003
52. US Food and Drug Administration Center for Biologics Evaluation and Research and the Society of Toxicology Workshop on Nonclinical Safety Evaluation of Preventive Vaccines, Recent Advances and Regulatory Considerations, transcript, December 2, 2002 Available from: http://www.fda.gov/cber/minutes/ tox120202.htm
53. Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev 1998;11(3):430-439
54. Sela M, Hilleman MR. Therapeutic vaccines: realities of today and hopes for tomorrow. PNAS 2004;101:14559
55. Koppele JT, Witkamp R. Use of animal models of disease in the preclinical safety evaluation of biopharmaceuticals. In: J Cavagnaro, editor, Preclinical safety evalution of biopharmaceuticals: a science-based approach to facilitating clinical trials, John Wiley & Sons, Hoboken, NJ; 2008. p. 293-308
56. Dixit R, Boelsterli UA. Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Discov Today 2007;12(7/8):336-342
57. Cavagnaro JA. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat Drug Discov 2002; 1:469-475
58. Sims J. Assessment of biotechnology products for therapeutic use. Toxicol Lett 2001;120:59-66
59. Dempster M. Designing non-clinical safety evaluation programmes: the view of the toxicologist. In: Briffith SA, Lumley CE, editors, Safety evaluation of biotechnology-derived pharmaceuticals: facilitating a scientific approach. Kluwer academic, Lancaster; 1998. p. 7-15
60. Arp LH. Tumor models: assessing toxicity in efficacy studies. Toxicol Pathol 1999;27:121-122
61. Yamada K, Nabeshima T. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol Ther 2000;88:93-113
62. Zak O, O'Reilly T. Animal models in the evaluation of antimicrobial agents. Antimicrob Agents Chemother 1991;35(8):1527-1531
63. Bugelski PJ, Herzyk DJ, Rehm S, et al. Preclinical development of keliximab, a Primatized® anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Hum Exp Toxicol 2000;19:230-243
64. Herzyk DJ, Gore ER, Polsky R, et al. Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in humanCD4transgenic mice. Infect Immunity 2001;69:1032-1043
65. Killeen N, Sawada S, Littman DR. Regulated expression of human CD4 rescues helper T cell development in mice lacking expression of endogenous CD4. EMBO J 1993;12(4):1547-1553
66. McLaughlin PM, Kroesen BJ, DokterWH, et al. An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy. Cancer Immunol Immunother 1999;48:303-411
67. Wells MY, Williams ES. The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies- implications for REACH. Regul Toxicol Pharmacol 2009;53:150-155
68. Bugelski PJ, Herzyk DJ, Rehm S, et al. Preclinical development of keliximab, a primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Human Exp Toxicol 2000;19(4):230-243